Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2021
![](/report_cover/8047/alpha-1-antitrypsin-deficiency-a1atd-liver-disease-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Overview
Alpha-1 antitrypsin is a large, 52?kDa serum glycoprotein and a serine protease inhibitor. Alpha-1 antitrypsin deficiency disease is an inherited metabolic disorder in which this protein is absent or defective. The protein Alpha-1 antitrypsin (AAT) is primarily synthesized and secreted by liver hepatocytes. Primary function depends on its secretion from the liver and its physiological action in the lungs to prevent excessive tissue destruction by neutrophil elastase. Alpha-Antitrypsin (AAT) Deficiency occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis.
'Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline landscape is provided which includes the disease overview and Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease treatment guidelines. The assessment part of the report embraces, in depth Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Emerging Drugs
Further product details are provided in the repor
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs segregated based on following parameters that define the scope of the report, such as:
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs.
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Overview
Alpha-1 antitrypsin is a large, 52?kDa serum glycoprotein and a serine protease inhibitor. Alpha-1 antitrypsin deficiency disease is an inherited metabolic disorder in which this protein is absent or defective. The protein Alpha-1 antitrypsin (AAT) is primarily synthesized and secreted by liver hepatocytes. Primary function depends on its secretion from the liver and its physiological action in the lungs to prevent excessive tissue destruction by neutrophil elastase. Alpha-Antitrypsin (AAT) Deficiency occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis.
'Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease pipeline landscape is provided which includes the disease overview and Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease treatment guidelines. The assessment part of the report embraces, in depth Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease R&D. The therapies under development are focused on novel approaches to treat/improve Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease.
This segment of the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Emerging Drugs
- ARO-AAT: Arrowhead Pharmaceuticals
- PHP 303: PH Pharmaceutical
- ZF874: Centessa Pharmaceuticals
Further product details are provided in the repor
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Subcutaneous
- Molecule Type
- Gene therapy
- RNAi
- Small interfering RNA
- Small molecule
- Product Type
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs.
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Report Insights
- Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs?
- How many Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arrowhead Pharmaceuticals
- PH Pharmaceutical
- Centessa Pharmaceuticals
- Novartis
- Vertex Pharmaceuticals
- Dicerna Pharmaceuticals
- Alnylam Pharmaceuticals
- Apic Bio
- LogicBio Therapeutics
- ARO-AAT
- PHP 303
- ZF874
- Carbamazepine
- VX-864
- Belcesiran
- ALN-AAT02
- APB-101
- LB 201
Introduction
Executive Summary
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
Comparative Analysis
ARO-AAT: Arrowhead Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ZF874: Centessa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Companies
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Products
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Unmet Needs
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Market Drivers and Barriers
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Future Perspectives and Conclusion
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Analyst Views
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Companies
Appendix
Executive Summary
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
Comparative Analysis
ARO-AAT: Arrowhead Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ZF874: Centessa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Companies
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Products
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Unmet Needs
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Market Drivers and Barriers
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease- Future Perspectives and Conclusion
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Analyst Views
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products